Prognostic and Clinicopathological Significance of Cyclin B Expression in Patients with Breast Cancer A Meta-Analysis

Liang Shi
DOI: https://doi.org/10.1097/md.0000000000006860
IF: 1.6
2017-01-01
Medicine
Abstract:Background: Cyclin B plays a crucial role in cancer cell cycle progression and is overexpressed in many human cancers, including breast cancer. However, the prognostic value of cyclin B expression in breast cancer is controversial. We performed a meta-analysis to assess the clinicopathological and prognostic significance of cyclin B expression in breast cancer.Methods: We searched PubMed, web of science, and Embase databases to retrieve the publications investigating the association between cyclin B expression and clinicopathological/prognostic significance in breast cancer patients. The pooled hazard ratio (HR) or odds ratio (OR) with its 95% confidence intervals (CIs) were used to estimate the effects.Results: Ten studies with 2366 breast cancer patients were included to evaluate the association between cyclin B expression and overall survival (OS), disease-free survival (DFS), disease-specific survival (DSS), and clinicopathological parameters. The results showed that cyclin B overexpression in breast cancer patients was significantly associated with both poor OS (univariate analysis: HR= 2.38, 95% CI= 1.72-3.30, P<. 001), DFS (univariate analysis: HR= 1.86, 95% CI= 1.50-2.32, P<. 001; multivariate analysis: HR= 1.75, 95% CI= 1.22-2.52, P=. 003), and DSS (multivariate analysis: HR= 5.42, 95% CI= 2.15-13.66, P<. 001). Additionally, cyclin B overexpression was significantly associated with lymphatic invasion (OR= 2.58, 95% CI= 1.03-6.46, P=. 017).Conclusion: Cyclin B overexpression appears to be an independent potential prognostic marker to DSS and DFS for breast cancer. Further studies with large sample size are needed to dissect the relationship between cyclin B and clinicopathological features or prognosis of breast cancer.
What problem does this paper attempt to address?